Pleasanton, Calif.-based Juvaris BioTherapeutics, a biotech developing vaccines and drugs against infectious disease, won a $9 million, five-year government grant to study adjuvants, which are substances that boost the body’s natural immune response. See our story at VentureBeat Life Sciences here.
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.